Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -39.18% is 23% above its 5-year average of -51.14%, near the high end of its 5-year range (-130.73%–-27.52%).
As of the fiscal period ended Tuesday, June 30, 2026. 26.51% above its 12-month average of -53.32%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -39.18%.
RETURN ON INVESTED CAPITAL (ROIC)
-39.18%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-53.32%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-52.54%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-51.14%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-65.52%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+26.51%
CURRENT VS 3Y AVG
+25.42%
CURRENT VS 5Y AVG
+23.39%
CURRENT VS 10Y AVG
+40.20%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.64%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
-9.92%
vs the sector median at left
Viridian Therapeutics, Inc.
Market Cap
$2.06B
Return on Invested Capital (ROIC)
-39.18%
TTM Avg
-53.32%
3Y Avg
-52.54%
5Y Avg
-51.14%
Market Cap
$2.06B
Return on Invested Capital (ROIC)
-45.19%
TTM Avg
-39.97%
3Y Avg
-37.50%
5Y Avg
-32.54%
Market Cap
$2.08B
Return on Invested Capital (ROIC)
3.61%
TTM Avg
5.05%
3Y Avg
-22.39%
5Y Avg
-28.34%
Market Cap
$2.05B
Return on Invested Capital (ROIC)
3.79%
TTM Avg
1.74%
3Y Avg
-1.46%
5Y Avg
-1.37%
Market Cap
$2.03B
Return on Invested Capital (ROIC)
15.47%
TTM Avg
9.87%
3Y Avg
8.85%
5Y Avg
8.76%
Market Cap
$2.02B
Return on Invested Capital (ROIC)
-89.73%
TTM Avg
-14.48%
3Y Avg
-24.76%
5Y Avg
-41.39%
Market Cap
$2.11B
Return on Invested Capital (ROIC)
-25.45%
TTM Avg
-178.48%
3Y Avg
-376.60%
5Y Avg
-259.41%
Market Cap
$2.02B
Return on Invested Capital (ROIC)
-34.96%
TTM Avg
-60.72%
3Y Avg
-59.19%
5Y Avg
-76.26%
Market Cap
$2.02B
Return on Invested Capital (ROIC)
21.77%
TTM Avg
7.57%
3Y Avg
-7.64%
5Y Avg
-15.11%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viridian Therapeutics, Inc. (VRDN) | $2.06B | -39.18% | -53.32% | -52.54% | -51.14% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | -45.19% | -39.97% | -37.50% | -32.54% |
| Alvotech (ALVO)vs › | $2.08B | 3.61% | 5.05% | -22.39% | -28.34% |
| Vericel Corporation (VCEL)vs › | $2.05B | 3.79% | 1.74% | -1.46% | -1.37% |
| Progyny, Inc. (PGNY)vs › | $2.03B | 15.47% | 9.87% | 8.85% | 8.76% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | -89.73% | -14.48% | -24.76% | -41.39% |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | -25.45% | -178.48% | -376.60% | -259.41% |
| UroGen Pharma Ltd. (URGN)vs › | $2.02B | -34.96% | -60.72% | -59.19% | -76.26% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 21.77% | 7.57% | -7.64% | -15.11% |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | -85.78% | -36.41% | -56.32% | -60.45% |
ROIC
-39.2%
ROE
-58.5%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -39.18% |
| 2026-03-31 | -52.27% |
| 2025-12-31 | -43.85% |
| 2025-09-30 | -62.24% |
| 2025-06-30 | -69.05% |
| 2025-03-31 | -53.73% |
| 2024-12-31 | -43.06% |
| 2024-09-30 | -38.74% |
| 2024-06-30 | -45.44% |
| 2024-03-31 | -39.37% |
| 2023-12-31 | -54.86% |
| 2023-09-30 | -75.95% |
| 2023-06-30 | -65.24% |
| 2023-03-31 | -50.66% |
| 2022-12-31 | -33.43% |
| 2022-09-30 | -27.52% |
| 2022-06-30 | -66.48% |
| 2022-03-31 | -51.61% |
| 2021-12-31 | -41.95% |
| 2021-09-30 | -68.28% |
| 2021-06-30 | -130.73% |
| 2021-03-31 | -113.63% |
| 2020-12-31 | -91.54% |
| 2020-09-30 | -99.57% |
| 2020-06-30 | -118.20% |
| 2020-03-31 | -111.28% |
| 2019-12-31 | -174.49% |
| 2019-09-30 | -130.74% |
| 2019-06-30 | -92.38% |
| 2019-03-31 | -78.23% |
| 2018-12-31 | -53.61% |
| 2018-09-30 | -40.82% |
| 2018-06-30 | -33.02% |
| 2018-03-31 | -29.22% |
| 2017-12-31 | -54.61% |
| 2017-09-30 | -60.31% |
| 2017-06-30 | -47.55% |
| 2017-03-31 | -31.84% |
| 2016-12-31 | -1739.64% |
| 2016-09-30 | -172.48% |
| 2016-06-30 | -149.72% |
| 2016-03-31 | -119.58% |
| 2015-12-31 | -96.95% |
| 2015-09-30 | -76.05% |
| 2015-06-30 | -74.16% |
| 2015-03-31 | -65.08% |
| 2014-12-31 | -112.57% |
| 2014-09-30 | -57.77% |
| 2014-06-30 | -35.55% |
| 2014-03-31 | -10.17% |
| 2013-12-31 | -6.58% |
